Comparing Xenon Pharmaceuticals (NASDAQ:XENE) & Stoke Therapeutics (NASDAQ:STOK)

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Xenon Pharmaceuticals and Stoke Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenon Pharmaceuticals 1 1 11 0 2.77
Stoke Therapeutics 1 0 10 0 2.82

Xenon Pharmaceuticals currently has a consensus target price of $71.15, suggesting a potential upside of 88.49%. Stoke Therapeutics has a consensus target price of $44.17, suggesting a potential upside of 65.48%. Given Xenon Pharmaceuticals’ higher possible upside, research analysts plainly believe Xenon Pharmaceuticals is more favorable than Stoke Therapeutics.

Profitability

This table compares Xenon Pharmaceuticals and Stoke Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenon Pharmaceuticals N/A -39.81% -37.98%
Stoke Therapeutics -862.07% -67.30% -58.52%

Volatility & Risk

Xenon Pharmaceuticals has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Earnings and Valuation

This table compares Xenon Pharmaceuticals and Stoke Therapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenon Pharmaceuticals $7.50 million 486.57 -$345.91 million ($4.70) -8.03
Stoke Therapeutics $184.42 million 9.47 -$6.89 million ($3.77) -7.08

Stoke Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Xenon Pharmaceuticals beats Stoke Therapeutics on 7 of the 13 factors compared between the two stocks.

About Xenon Pharmaceuticals

(Get Free Report)

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.